ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

• Status: Completed
• Trial end date: 2018-10-18
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ophthotech Corporation
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Active subfoveal NVAMD

Exclusion Criteria:

• History or evidence of severe cardiac disease

• Any major surgical procedure within one month of trial entry

• Subjects with a clinically significant laboratory value

• Any treatment with an investigational agent in the past 60 days for any condition

• Women who are pregnant or nursing

• Known serious allergies to the fluorescein dye used in angiography, povidone iodine, to the components of the ranibizumab formulation, or to the components of the Zimura formulation

• Any prior treatment for AMD other than oral supplements of vitamins and minerals